Brief: Bioinvent Regains Rights To Immuno-Oncology Targets From Exelixis

BioInvent International AB

12/01/2024 07:04

Jan 12 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT REGAINS RIGHTS TO IMMUNO-ONCOLOGY TARGETS FROM
EXELIXIS
    * COMPANIES WILL COLLABORATE ON A WIND-DOWN AND EFFECTIVE
TRANSITION OVER NEXT 90 DAYS

Source text for Eikon:  ID:nMFN74CHZ1 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))